Botulinum Toxin for the Treatment of Facial Flushing

Dermatologic Surgery

Volumn 30, Issue 1, 2004, Pages 102-104

  Yuraitis, Melanie ^a   Jacob, Carolyn I ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Adv Skin and Mohs Surgery Center   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CLONIDINE; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; ERYTHEMA; FLUSHING; HUMAN; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PULSED DYE LASER; SKIN DISEASE; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXIN TYPE A; FLUSHING; HUMANS; MALE; NEUROMUSCULAR AGENTS;

EID: 0842333118     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30017.x     Document Type: Article

References (18)

1. Dover JS, Arndt KA. New approaches to the treatment of vascular lesions. Lasers Surg Med 2000;26:158-63.
2. Travelute Ammirati C, Carniol PJ, Hruza GJ. Laser treatment of facial vascular lesions. Facial Plast Surg 2001;12:193-201.
3. Angermeier MC. Treatment of facial vascular lesions with intense pulsed light. J Cutan Laser Ther 1999;1:95-100.
4. Wilkin. Erythromelalgia, erythermalgia, and flushing. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, eds. Cutaneous Medicine and Surgery. Philadelphia: W.B. Saunders, 1996:533-6.
5. Bravo EL, Gifford RW. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984;311:1298-303.
6. Landsberg L, Young JB. Pheochromocytoma. In: Braunwald E, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001:2105-9.
7. Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Braunwald E, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001:593-603.
8. Austen KF. Allergies, anaphylaxis, and systemic mastocytosis. In: Braunwald E, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001:1913-21.
9. Scher HL. Bladder and renal cell carcinomas. In: Braunwald E, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001-604-8.
10. Matarasso S. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003;29:7-13.
11. Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 2002;47:667-71.
12. Naumann MK, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002;147:1218-26.
13. Salmanpoor R, Rahmanian MJ. Treatment of axillary hyperhidrosis with botulinum-A toxin. Int J Dermatol 2002;41:428-30.
14. Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 2002;28:480-3.
15. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28:822-7.
16. Hofmann RJ. Treatment of Frey's syndrome (gustatory sweating) and "crocodile tears" (gustatory epiphora) with purified botulinum toxin. Ophtal Plast Recontr Surg 2000;16:289-91.
17. Brich JF, Varma SK, Narula AA. Botulinum toxoid in the management of gustatory sweating (Frey's syndrome) after superficial parotidectomy. Br J Plast Surg 1999;52:230-1.
18. Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey's syndrome. Otolaryngol Head Neck Surg 2000;122:237-40.